Last reviewed · How we verify
IV Nivolumab
IV Nivolumab is a Small molecule drug developed by National Cancer Centre, Singapore. It is currently in Phase 1 development. Also known as: Opdivo.
At a glance
| Generic name | IV Nivolumab |
|---|---|
| Also known as | Opdivo |
| Sponsor | National Cancer Centre, Singapore |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Diarrhoea
- Nausea
- Pruritus
- Headache
- Rash
- Cough
- Arthralgia
- Decreased appetite
- Asthenia
- Constipation
- Hypothyroidism
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PHASE3)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (PHASE1)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Nivolumab CI brief — competitive landscape report
- IV Nivolumab updates RSS · CI watch RSS
- National Cancer Centre, Singapore portfolio CI
Frequently asked questions about IV Nivolumab
What is IV Nivolumab?
IV Nivolumab is a Small molecule drug developed by National Cancer Centre, Singapore.
Who makes IV Nivolumab?
IV Nivolumab is developed by National Cancer Centre, Singapore (see full National Cancer Centre, Singapore pipeline at /company/national-cancer-centre-singapore).
Is IV Nivolumab also known as anything else?
IV Nivolumab is also known as Opdivo.
What development phase is IV Nivolumab in?
IV Nivolumab is in Phase 1.
What are the side effects of IV Nivolumab?
Common side effects of IV Nivolumab include Fatigue, Diarrhoea, Nausea, Pruritus, Headache, Rash.
Related
- Manufacturer: National Cancer Centre, Singapore — full pipeline
- Also known as: Opdivo
- Compare: IV Nivolumab vs similar drugs
- Pricing: IV Nivolumab cost, discount & access